[Form 4] Altimmune, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Altimmune (ALT) reported a Form 4 for its Chief Financial Officer detailing new equity awards granted on October 1, 2025.

The filing shows stock options for 166,800 shares at an exercise price of $3.87, expiring on October 1, 2035, and 57,900 restricted stock units. The options vest over four years: 25% on October 1, 2026, then in equal monthly installments over the following 36 months. The RSUs vest over four years: 25% on October 1, 2026, then in equal annual installments for the next three years. The awards are reported as held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEAVER GREGORY L

(Last) (First) (Middle)

C/O ALTIMMUNE, INC.

910 CLOPPER ROAD, SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (option to buy)	$3.87	10/01/2025		A		166,800		(1)	10/01/2035	Common Stock, par value $0.0001	166,800	$0.00	166,800	D
Restricted Stock Units	(2)	10/01/2025		A		57,900		(3)	(3)	Common Stock, par value $0.0001	57,900	$0.00	57,900	D

Explanation of Responses:

1. The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested

3. The RSUs become vested over four (4) years with 25% of the shares vesting October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

	/s/ Gregory Weaver as Attorney-in Fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Altimmune (ALT) grant to its CFO?

The CFO received stock options for 166,800 shares and 57,900 RSUs.

What is the exercise price and expiration for the CFO’s stock options at ALT?

The options have a $3.87 exercise price and expire on October 1, 2035.

How do the CFO’s stock options vest at Altimmune (ALT)?

They vest over four years: 25% on October 1, 2026, then in equal monthly installments for 36 months.

What is the vesting schedule for the CFO’s RSUs at ALT?

RSUs vest over four years: 25% on October 1, 2026, then equal annual installments for three years.

When was the transaction date for the reported ALT awards?

The transaction date was October 1, 2025.

How are the reported ALT awards held?

They are reported as held directly by the CFO.